The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53

REFERENCES

• Barak, Y., T. Juven, R. Haffner, and M. Oren 1993. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461–468.
   PubMed Web of Science ®Google Scholar
• Bender, C. M., M. M. Pao, and P. A. Jones 1998. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58: 95–101.
   PubMed Web of Science ®Google Scholar
• Bird, A. 1986. CpG-Rich islands and the function of DNA methylation. Nature 321: 209–213.
   PubMed Web of Science ®Google Scholar
• Caldas, C., S. A. Hahn, L. T. daCosta, M. S. Redston, M. Schutte, A. B. Seymour, C. L. Weinstein, R. H. Hruban, C. J. Yeo, and S. E. Kern 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27–32.
   PubMed Web of Science ®Google Scholar
• Carcamo, J., L. Buckbinder, and D. Reinberg 1991. The initiator directs the assembly of a transcription factor IID-dependent transcription complex. Proc. Natl. Acad. Sci. USA 88: 8052–8056.
   PubMedGoogle Scholar
• Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Nature 255: 459–462.
   Google Scholar
• Corbin, V., and T. Maniatis 1989. Role of transcriptional interference in the Drosophila melanogaster Adh promoter switch. Nature 337: 279–282.
   PubMed Web of Science ®Google Scholar
• Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817–827.
   PubMedGoogle Scholar
• DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J. R. Nevins 1997. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA 94: 7245–7250.
   PubMed Web of Science ®Google Scholar
• Efstratiadis, A. 1994. Parental imprinting of autosomal mammalian genes. Curr. Opin. Genet. Dev. 4: 265–280.
   PubMed Web of Science ®Google Scholar
• Fitzgerald, M. G., D. P. Harkin, S. Silva-Arrieta, D. J. MacDonald, L. C. Lucchina, H. Unsal, E. O’Neill, J. Koh, D. M. Finkelstein, K. J. Isselbacher, A. J. Sober, and D. A. Haber 1996. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA 93: 8541–8545.
   PubMed Web of Science ®Google Scholar
• Gardiner-Garden, M., and M. Frommer 1987. CpG islands in vertebrate genomes. J. Mol. Biol. 196: 261–282.
   PubMed Web of Science ®Google Scholar
• Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren 1991. Wild-type p53 can down-regulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88: 9979–9983.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Zulueta, M., C. M. Bender, A. S. Yang, T.-D. Nguyen, R. W. Beart, J. M. VanTornout, and P. A. Jones 1995. Methylation of the CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55: 4531–4535.
   PubMed Web of Science ®Google Scholar
• Gonzalgo, M. L., T. Hayashida, C. M. Bender, M. M. Pao, Y. C. Tsai, F. A. Gonzales, H. D. Nguyen, T.-D. Nguyen, and P. A. Jones 1998. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res. 58: 1245–1252.
   PubMed Web of Science ®Google Scholar
• Haber, D. A. 1997. Splicing into senescence: the curious case of p16 and p19ARF. Cell 91: 555–558.
   PubMed Web of Science ®Google Scholar
• Hall, M., and G. Peters 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 68: 67–108.
   PubMed Web of Science ®Google Scholar
• Hara, E., R. Smith, D. Parry, H. Tahara, S. Stone, and G. Peters 1996. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16: 859–867.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
   PubMed Web of Science ®Google Scholar
• Herman, J. G., J. Jen, A. Merlo, and S. B. Baylin 1996. Hypermethylation associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 54: 722–727.
   Google Scholar
• Herman, J. G., A. Merlo, L. Mao, R. G. Lapidus, J. P. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55: 4525–4530.
   PubMed Web of Science ®Google Scholar
• Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22: 3551–3555.
   PubMed Web of Science ®Google Scholar
• Hussussian, C. J., J. P. Struewing, A. M. Goldstein, P. A. T. Higgins, D. S. Ally, M. D. Sheahan, W. H. Clark, M. A. Tucker, and N. C. Dracopoli 1994. Germline p16 mutations in familial melanoma. Nat. Genet. 8: 15–21.
   PubMed Web of Science ®Google Scholar
• Jones, N. C., P. W. Rigby, and E. B. Ziff 1988. Trans-acting protein factors and the regulation of eukaryotic transcription: lessons from studies on DNA tumor viruses. Genes Dev. 2: 267–281.
   PubMedGoogle Scholar
• Jones, P. A., M. J. Wolkowicz, Rideout W. M., III, F. A. Gonzales, C. M. Marziasz, G. Coetzee, and S. J. Tapscott 1990. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl. Acad. Sci. USA 87: 6117–6121.
   PubMed Web of Science ®Google Scholar
• Kamb, A., D. Shattuck-Eidens, R. Eeles, Q. Liu, N. A. Gruis, W. Ding, C. Hussey, T. Tran, Y. Miki, J. Weaver-Feldhaus, M. McClure, J. F. Aitken, D. E. Anderson, W. Bergman, R. Frants, D. E. Goldgar, A. Green, R. MacLennan, N. G. Martin, L. J. Meyer, P. Youl, J. J. Zone, M. H. Skolnick, and L. A. Cannon-Albright 1994. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8: 22–26.
   Web of Science ®Google Scholar
• Kamijo, T., F. Zindy, M. F. Roussel, D. Q. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649–659.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304–6311.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives 1996. p53: Puzzle and paradigm. Genes Dev. 10: 1054–1072.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden 1997. Regulation of p53 stability by mdm2. Nature 387: 299–303.
   PubMed Web of Science ®Google Scholar
• Larsen, C.-J. 1996. p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene 12: 2041–2044.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
   PubMed Web of Science ®Google Scholar
• Liggett, W. H., D. A. Sewell, J. Rocco, S. A. Ahrendt, W. Koch, and D. Sidransky 1996. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res. 56: 4119–4123.
   PubMed Web of Science ®Google Scholar
• Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laimins 1993. Specific repression of TATA-mediated but not initiator-mediated transcription repression by wild-type p53. Nature 363: 281–283.
   PubMed Web of Science ®Google Scholar
• Macleod, D., J. Charlton, J. Mullins, and A. P. Bird 1994. Sp1 sites in the mouse Aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev. 8: 2282–2292.
   PubMed Web of Science ®Google Scholar
• Mao, L., A. Merlo, G. Bedi, G. I. Shapiro, C. D. Edwards, B. J. Rollins, and D. Sidransky 1995. A novel p16INK4A transcript. Cancer Res. 55: 2995–2997.
   PubMed Web of Science ®Google Scholar
• Means, A. L., and P. J. Farnham 1990. Transcriptional initiation from the dihydrofolate reductase promoter is positioned by HIP-1 binding at the initiation site. Mol. Cell. Biol 10: 653–661.
   PubMedGoogle Scholar
• Mercer, W. E., M. T. Shields, D. Lin, E. Appella, and S. J. Ullrich 1991. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA 88: 1958–1962.
   PubMed Web of Science ®Google Scholar
• Merlo, A., J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin, and D. Sidransky 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1: 686–692.
   PubMed Web of Science ®Google Scholar
• Moran, E. 1993. DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. 3: 63–70.
   PubMed Web of Science ®Google Scholar
• Nelson, W. G., and M. B. Kastan 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14: 1815–1823.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80–83.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857–860.
   PubMed Web of Science ®Google Scholar
• Parry, D., S. Bates, D. J. Mann, and G. Peters 1995. Lack of cyclin D-cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumor suppressor gene product. EMBO J. 14: 503–511.
   PubMed Web of Science ®Google Scholar
• Perry, M. E., and A. J. Levine 1993. Tumor-suppressor p53 and the cell cycle. Curr. Opin. Genet. Dev. 3: 50–54.
   PubMedGoogle Scholar
• Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. El-Deiry, K. W. Kinzler, and B. Vogelstein 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91: 1998–2002.
   PubMed Web of Science ®Google Scholar
• Polyak, K., T. Waldman, T.-C. He, K. W. Kinzler, and B. Vogelstein 1996. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10: 1945–1952.
   PubMed Web of Science ®Google Scholar
• Pomerantz, J., N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H.-W. Lee, C. Cordon-Cardo, and R. A. DePinho 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 92: 713–723.
   PubMed Web of Science ®Google Scholar
• Proudfoot, N. J. 1986. Transcriptional interference and termination between duplicated α-globin gene constructs suggests a novel mechanism for gene regulation. Nature 322: 562–565.
   PubMed Web of Science ®Google Scholar
• Puglielli, M. T., N. Desai, and S. H. Speck 1997. Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). J. Virol. 71: 120–128.
   PubMedGoogle Scholar
• Quelle, D. E., M. Cheng, R. A. Ashmun, and C. J. Sherr 1997. Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not the alternative reading frame protein p19ARF. Proc. Natl. Acad. Sci. USA 94: 669–673.
   PubMed Web of Science ®Google Scholar
• Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000.
   PubMed Web of Science ®Google Scholar
• Rashbaum, S. A., and N. R. Cozzarelli 1976. Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine. Nature 264: 679.
   PubMedGoogle Scholar
• Reich, N. C., and A. J. Levine 1984. Growth regulation of a cellular tumor antigen, p53, in nontransformed cells. Nature 308: 199–201.
   PubMed Web of Science ®Google Scholar
• Robertson, K. D., and R. F. Ambinder 1997. Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. J. Virol. 71: 6445–6454.
   PubMedGoogle Scholar
• Robertson, K. D., S. D. Hayward, P. D. Ling, D. Samid, and R. F. Ambinder 1995. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol. Cell. Biol. 15: 6150–6159.
   PubMedGoogle Scholar
• Rozenblum, E., M. Schutte, M. Goggins, S. A. Hahn, S. Panzer, M. Zahurak, S. N. Goodman, T. A. Sohn, R. H. Hruban, C. J. Yeo, and S. E. Kern 1997. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57: 1731–1734.
   PubMed Web of Science ®Google Scholar
• Santhanam, U., A. Ray, and P. B. Sehgal 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 88: 7605–7609.
   PubMed Web of Science ®Google Scholar
• Schutte, M., R. H. Hruban, J. Geradts, R. Maynard, W. Hilgers, S. K. Rabindran, C. A. Moskaluk, S. A. Hahn, I. Schwarte-Waldhoff, W. Schmiegel, S. B. Baylin, S. E. Kern, and J. G. Herman 1997. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57: 3126–3130.
   PubMed Web of Science ®Google Scholar
• Serrano, M., G. J. Hannon, and D. Beach 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707.
   PubMed Web of Science ®Google Scholar
• Serrano, M., H.-W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27–37.
   PubMed Web of Science ®Google Scholar
• Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89: 12028–12032.
   PubMed Web of Science ®Google Scholar
• Sewell, D. A., Liggett, W. H.Jr., W. G. Yarbrough, and D. Sidransky 1997. Human p16β encodes a novel 14 kD protein and suppresses growth in vitro independently from pRb. Proc. Am. Assoc Cancer Res. 38: 80.
   Google Scholar
• Sherr, C. J. 1996. Cancer cell cycles. Science 276: 1672–1677.
   Google Scholar
• Shores, C., E. Liu, and W. Yarbrough 1997. Expression of p16β in human cells. Proc. Am. Assoc. Cancer Res. 38: 277.
   Google Scholar
• Shrivastava, A., and K. Calame 1994. An analysis of genes regulated by the multi-functional transcriptional regulator Yin Yang-1. Nucleic Acids Res. 22: 5151–5155.
   PubMed Web of Science ®Google Scholar
• Smale, S. T., and D. Baltimore 1989. The “initiator” as a transcriptional control element. Cell 57: 103–113.
   PubMed Web of Science ®Google Scholar
• Stone, S., P. Jiang, P. Dayananth, S. V. Tavtigian, H. Katcher, D. Parry, G. Peters, and A. Kamb 1995. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res. 55: 2988–2994.
   PubMed Web of Science ®Google Scholar
• Subler, M. A., D. W. Martin, and S. Deb 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66: 4757–4762.
   PubMedGoogle Scholar
• Tam, S. W., J. W. Shay, and M. Pagano 1994. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res. 54: 5816–5820.
   PubMed Web of Science ®Google Scholar
• Tanaka, H., Y. Shimada, M. Imamura, I. Shabagaki, and K. Ishizaki 1997. Multiple types of aberrations in the p16(INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Int. J. Cancer 70: 437–442.
   PubMedGoogle Scholar
• Trimarchi, J. M., B. Fairchild, R. Verona, K. Moberg, N. Andon, and J. A. Lees 1998. E2F-6, a member of the E2F family that can behave as a transcriptional repressor. Proc. Natl. Acad. Sci. USA 95: 2850–2855.
   PubMed Web of Science ®Google Scholar
• Tuck, S. P., and L. Crawford 1989. Characterization of the human p53 gene promoter. Mol. Cell. Biol. 9: 2163–2172.
   PubMed Web of Science ®Google Scholar
• Vales, L. D., and J. E. Darnell 1989. Promoter occlusion prevents transcription of Adenovirus polypeptide IX mRNA until after DNA replication. Genes Dev. 3: 49–59.
   PubMedGoogle Scholar
• Wu, J., G. J. Grindlay, P. Bushel, L. Mendelsohn, and M. Allan 1990. Negative regulation of the human ɛ-globin gene by transcriptional interference: role of an Alu repetitive element. Mol. Cell. Biol. 10: 1209–1216.
   PubMedGoogle Scholar
• Wu, X., J. H. Bayle, D. Olsen, and A. J. Levine 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126–1132.
   PubMed Web of Science ®Google Scholar
• Xu, Z.-P., and G. F. Saunders 1997. Transcriptional regulation of the human PAX6 gene promoter. J. Biol. Chem. 272: 3430–3436.
   PubMedGoogle Scholar
• Zhang, Y., Y. Xiong, and W. G. Yarbrough 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734.
   PubMed Web of Science ®Google Scholar